Founded by Ariel Garten (BSc 2002), MUSE secures Series C funding

August 8, 2022 by Business Wire

Interaxon Inc. (Muse®), the leading consumer neurotechnology company, announced that it has closed an oversubscribed $9.5M USD Series C funding round through a non-brokered private placement. The round was led by BDC Capital, Alabaster (family office of Sunny Vu, founder of Misfit), and Export Development Canada, along with new institutional investors including Phyto Partners, Iter Investments, Intretech(HK) Co, and The Clavis Foundation.

With this funding, Interaxon aims to enrich its leading brain health platform through launching an integrated wellness membership model and further research and validation of an industry-first feature tracking longitudinal changes in the brain. Interaxon will also support expanding offerings for third-party developers, researchers, clinicians and other strategic partnerships.

“At Muse, we’re passionate about supporting the neuroscience research community,” said Ariel Garten (BSc 2002), co-founder of Interaxon. “We are excited for the value this funding will unlock, including the development and validation of an industry first, user-friendly EEG measurement showing changes in brain age that can provide value in a variety of research and clinical settings.”

Read full article here